Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) FCF Margin (2019 - 2025)

Historic FCF Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 280.58%.

  • C4 Therapeutics' FCF Margin fell 1235700.0% to 280.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 314.8%, marking a year-over-year decrease of 1022100.0%. This contributed to the annual value of 183.61% for FY2024, which is 3393500.0% up from last year.
  • Latest data reveals that C4 Therapeutics reported FCF Margin of 280.58% as of Q3 2025, which was down 1235700.0% from 186.55% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' FCF Margin registered a high of 43.07% during Q2 2024, and its lowest value of 1072.81% during Q4 2022.
  • Its 5-year average for FCF Margin is 401.4%, with a median of 345.49% in 2021.
  • As far as peak fluctuations go, C4 Therapeutics' FCF Margin plummeted by -9444100bps in 2022, and later soared by 6836200bps in 2024.
  • Over the past 5 years, C4 Therapeutics' FCF Margin (Quarter) stood at 128.4% in 2021, then tumbled by -736bps to 1072.81% in 2022, then skyrocketed by 31bps to 741.06% in 2023, then soared by 53bps to 346.3% in 2024, then grew by 19bps to 280.58% in 2025.
  • Its FCF Margin was 280.58% in Q3 2025, compared to 186.55% in Q2 2025 and 459.86% in Q1 2025.